PQR309 is a novel dual PI3K/mTOR inhibitor with antitumor pre-clinical activity in lymphomas as single agent and in combination. Homo sapiens
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA371789
下载链接
链接失效反馈官方服务：
资源简介：
assess the efficacy of dual PI3K/mTOR inhibitor with anti-lymphoma activity as single agent and in combination Overall design: GEP analysis of 8 lymphoma cell lines with and without treatment
创建时间：
2017-02-08
